A Phase I, Open-Label Study to Determine Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of SH3051 Capsule in Patients With Advanced Solid Tumors
Latest Information Update: 07 Jun 2022
At a glance
- Drugs SH 3051 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Nanjing Sanhome Pharmaceutical
Most Recent Events
- 11 Jun 2020 New trial record